Protein translation is divided into three general steps, initiation, elongation and termination. Each step has a number of specialized proteins, termed eukaryotic initiation factors (eIFs), eukaryotic elongation factors (eEFs) and eukaryotic release factors. Each of these steps is known to be regulated to carefully adjust protein translation rates to the requirements of the cell. Moreover, translation of individual mRNAs can be regulated independently of each other in a manner dependent on specific sequences in their untranslated regions (UTRs). Through a combination of global and specific control, the complement of proteins translated in a given cell can be matched to the environmental conditions, via a relay of signal transduction pathways. The best understood mechanisms for regulating protein translation are at the initiation step, which can be simplistically divided into two parts, which occur independently of each other. The first part involves binding of the mRNA to eIF4E via its 5 0 modified guanosine nucleoside, methyl 7-guanosine triphosphate (m 7 GTP-cap), which is present in all nuclear transcribed mRNAs. eIF4E is part of the eIF4F complex, consisting of the scaffold protein eIF4G and the RNA helicase eIF4A. Additional proteins, including eIF4B (which stimulates the activity of eIF4A), and poly A binding protein (PABP, which binds the 3 0 polyadenylated terminus of the mRNA), are also recruited into this complex. The second part involves association of the initiating methionine transfer RNA (Met-tRNA) with the eIF2.GTP heterotrimer (eIF2a,b,g, the latter subunit binding GTP). The eIF2.GTP.Met-tRNA trimer is termed ternary complex, and is transferred to the 40S small ribosomal subunit in association with three additional initiation factors eIF3, eIF1A and eIF5, forming the 43S preinitiation complex. This 43S preinitiation complex has increased affinity to mRNA bound to eIF4F, and following assembly, the helicase activity of eIF4A unwinds secondary structure present in the 5 0 UTR of the mRNA, allowing scanning for the presence of the initiating methionine AUG (Hershey and Merrick, 2000) . Although all three steps in translation are tightly controlled, the initiation step appears to be the most commonly targeted by signal transduction pathways deregulated in cancer.
Translational control as an important target of common oncogenes and tumor suppressors
The PI3-kinase pathway is activated in many human tumors One of the most commonly mutated tumor suppressor genes in human cancer is phosphatase and tensin homologue deleted on chromosome 10 (PTEN). PTEN is a phospholipid phosphatase that antagonizes the activity of phosphoinositide 3-kinase (PI3-kinase), by dephosphorylating its lipid product phosphatidylinositol (3, 4, 5) trisphosphate (PtdIns(3,4,5)P3) (Leslie and Downes, 2002) . PI3-kinase is itself a bona fide human oncogene, as one of its catalytic subunits is either amplified (Shayesteh et al., 1999) or mutated (Samuels and Velculescu, 2004) in many human tumors. In addition, PI3-kinase is activated by many growth factor receptors that are themselves mutated and/or amplified in tumors, as well as by Ras, another commonly mutated gene in human cancer. Generation of PtdIns(3,4,5)P3 recruits a number of proteins containing pleckstrin homology domains to the site of accumulation. This triggers the activation of numerous downstream signaling proteins including the activation of tyrosine kinases, serine/ threonine kinases and small G proteins (Stephens et al., 2005; Stokoe, 2005) . Activation of PI3-kinase causes a plethora of distinct biological events including cell proliferation, growth, survival, metabolism, migration and membrane trafficking. The exact outcome likely depends on the particular stimulus and the cell type involved. The best characterized and most studied PI3-kinase downstream pathway involves the activation of protein kinase B (PKB, also known as Akt, and here referred to as PKB/Akt). PKB/Akt is able to phosphorylate a large number of substrates (reviewed in Vanhaesebroeck and Alessi, 2000) , which regulate many important biological pathways. Forced overexpression of activated PKB/Akt from various promoters in transgenic mice has been shown to be sufficient to induce hyperplasia and/or hypertrophy, often causing the development of benign tumors (reviewed in Yang et al., 2004b) . Combination of PKB/Akt activation with additional genetic lesions such as overexpression of oncogenes or deletion of tumor suppressor genes generates malignant growth (e.g., Holland et al., 2000) . mTORC1 as an important downstream target of PI3-kinase activity An important question pertinent to understanding the role of PI3-kinase and PKB/Akt in tumorigenesis is which downstream substrates and pathways are the most critical during this process. Some recent experiments have helped shed light on this complex question. For example, expression of an activated form of PKB/ Akt driven by the probasin promoter that restricts expression to the ventral prostate results in prostate intraepithelial neoplasia (PIN) in these regions. Remarkably, inhibition of just one of the downstream pathways of PKB/Akt using the macrolide drug rapamycin was sufficient to completely reverse the PIN phenotype induced by activated PKB/Akt (Majumder et al., 2004) . Similarly, in a mouse model of B-cell lymphoma, in which c-myc is overexpressed using the Em immunoglobulin enhancer, lymphomagenesis is enhanced by co-overexpression of either PKB/Akt or Bcl2. Although addition of rapamycin was not sufficient to regress tumors in this model, it synergized with chemotherapeutic agents to extend the lifespan of mice expressing both myc and PKB/Akt transgenes. This was not a general antitumor effect of rapamycin, as it was ineffective in mice expressing myc and Bcl2 (Wendel et al., 2004) .
As rapamycin was able to reverse tumorigenesis induced by activated PKB/Akt, the target of rapamycin must be a critical downstream effector of PKB/Akt in this process. Rapamycin binds directly to FK506-binding protein 12 (FKBP12), and this complex binds to the protein kinase mTOR. This prevents the ability of mTOR to phosphorylate some of its substrates, those phosphorylated by the mTOR complex-1, or mTORC1 (Oshiro et al., 2004) . mTORC1 consists of mTOR, raptor and mLST8 (Figure 1 ), whereas mTORC2 consists of mTOR, rictor, mLST8 and mSin1 (Guertin et al., 2006) . A recent paper from Hay and colleagues (Skeen et al., 2006) has further genetically implicated mTORC1 as the most important downstream target of PKB/Akt in initiating tumorigenesis. It is still not entirely resolved how PKB/Akt stimulates mTORC1 activity. mTORC1 activity is stimulated by a small GTPase termed Rheb, which in turn is inhibited by the GTPase-activating protein (GAP) activity of the tuberous sclerosis (TSC1/TSC2) complex. PKB/Akt can directly phosphorylate TSC2, and this has been proposed to inhibit the GAP activity of the TSC1/TSC2 complex (reviewed in McManus and Alessi, 2002 ). An alternative hypothesis also involves phosphorylation of TSC2, but in this case indirectly by the AMP-activated protein kinase (AMPK). In this scenario PKB/Akt activity results in elevated cellular ATP levels, thereby inhibiting the activity of AMPK activity and preventing the stimulatory phosphorylation of TSC2 by AMPK (Hahn-Windgassen et al., 2005) . Although mTORC1 has been reported to phosphorylate several substrates (reviewed in Yonezawa et al., 2004) , the best characterized so far are p70 ribosomal protein S6 kinase (S6K) and the eIF 4E-binding protein (4E-BP1) (Figure 1 ). Both of these substrates have been implicated in regulating mRNA translation.
4E-BP1 as a target of mTORC1 activity and translational responses 4E-BP1 acts as an inhibitor of the 5 0 cap-binding protein eIF4E, by competitively preventing its binding to eIF4G. Phosphorylation of 4E-BP1 by mTORC1 releases it from eIF4E, thereby allowing assembly of the eIF4F complex with 5 0 capped mRNAs (reviewed in Yonezawa et al., 2004) . Although this might be expected to implicate phosphorylation of 4E-BP1 in the global stimulation of translation initiation, this has not been borne out from empirical observations. In fact, treatment of mammalian cells with rapamycin causes only a small reduction in total protein synthesis (Jefferies et al., 1994; Beretta et al., 1996) . Similarly, overexpression of eIF4E only modestly increases total protein synthesis. Instead, mRNAs containing long and structured 5 0 UTRs are thought to be particularly sensitive to this mechanism of regulation, perhaps owing to the recruitment of an RNA helicase (eIF4A) into the eIF4F complex. Although the identities of all the mRNAs most sensitive to eIF4F activity, as well as the mechanisms underlying this remain to be fully resolved, some important insights have already been generated.
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Overexpression of eIF4E in NIH3T3 cells increases the translation of cyclin D1 and ornithine decarboxylase (ODC) (Rousseau et al., 1996) . Similarly, overexpression of eIF4E in Chinese hamster ovary cells increases the protein levels of c-myc, FGF2 and VEGF (Kevil et al., 1996; De Benedetti and Harris, 1999) . The 5 0 UTRs of these mRNAs are generally long and structured, with a high percentage of GC nucleotides, leading to the notion that such UTRs are under the influence of eIF4F activity. However, the regulation of translation by eIF4E may be more complex than merely through unwinding of secondary structure. For example, the effect of eIF4E on stimulating cyclin D1 translation is thought to be through an element in its 3 0 UTR regulating nuclear export (Culjkovic et al., 2005) . In addition, overexpression of eIF4E in cardiomyocytes did not stimulate the translation of chimeric reporter mRNAs with increased secondary structure (Tuxworth et al., 2004) . Finally, in an empirical analysis of mRNAs translationally stimulated following constitutive overexpression of eIF4E in NIH3T3 cells, there was no obvious enrichment for either long structured 5 0 UTRs, or for many of the mRNAs mentioned above (with the exception of ODC; Larsson et al., 2006) . Instead, a novel 55-mer element showing two stem loops was present in the 5 0 UTRs of mRNAs selected in this analysis. Transient overexpression of eIF4E in NIH3T3 cells also did not cause increased polysome recruitment of the mRNAs mentioned above (Mamane et al., 2007) . In sum, more work is required to fully understand which mRNAs are regulated by mTORC1-dependent regulation of eIF4F activity, and by which mechanisms this may occur.
S6K as a target of mTORC1 and translational consequences
The other major substrate of mTORC1 is S6K. This protein exists as two isoforms, S6K1 and S6K2, both of which have two splice variants. Although it was named after its ability to phosphorylate the small ribosomal protein S6, S6K phosphorylates a number of substrates (recently reviewed in Ruvinsky and Meyuhas, 2006) . In addition to S6, S6K phosphorylates two other proteins that are important in regulating mRNA translation, namely eIF4B and eEF2K. The ability of S6K to phosphorylate its substrates involved in mRNA translation may be controlled through regulated interactions with the translation initiation factor eIF3 complex (Holz et al., 2005) . Phosphorylation of eIF4B by S6K is thought to stimulate the activity of the eIF4A helicase (Raught et al., 2004) , therefore, simultaneous 4E-BP1 and eIF4B phosphorylation downstream of mTORC1 may help to coordinate the translation of structured 5 0 UTRs as described in the previous section. eEF2K phosphorylates and inhibits the activity of eEF2, a critical enzyme involved in translational elongation. Phosphorylation of eEF2K by S6K inhibits the activity of eEF2K, thereby stimulating translational elongation. Therefore, S6K activity may stimulate both the initiation and elongation phases of translation. The role of phosphorylation of its third substrate S6 remains somewhat mysterious. S6 is a component of the 40S small ribosomal subunit, and is phosphorylated on five serine residues following mitogenic stimuli. S6 phosphorylation has long been implicated in the translation of a particular subclass of mRNAs, those with terminal oligopyrimidine (TOP) tracts in the 5 0 UTR. This Mamane et al. (2007) .
Translational deregulation in human tumors B Bilanges and D Stokoe conclusion was reached mainly through correlative studies examining the effects of rapamycin, or dominant-interfering mutants of S6K1 on the translation of TOP-containing mRNAs (e.g., in Jefferies et al., 1997) .
On the contrary, more recent direct analyses of S6 phosphorylation have shown that this is unlikely to be the case. Knockouts of individual isoforms of S6K has shown that loss of S6K1 has little effect on S6 phosphorylation, loss of S6K2 has a partial effect, and loss of both S6K1 and S6K2 almost completely abolished mitogen-induced S6 phosphorylation. However, this had no effect on the mitogen-induced recruitment of eEF1A, a representative TOP mRNA, into polysomes (Pende et al., 2004) . Similarly, cells from a mouse expressing serine to alanine substitutions in all five S6 phosphorylation sites showed identical polysomal distribution of TOP-containing mRNAs such as RPL32, RPS6 and RPS16 (Ruvinsky et al., 2005) . Surprisingly, global protein synthesis was actually enhanced in cells from these mice (Ruvinsky et al., 2005) . Therefore, while S6K probably plays a general role to increase mRNA translation, the exact mechanisms and substrates involved remain to be fully elucidated.
A recently described substrate of S6K that impacts mRNA translation is the programmed cell death protein 4 (PDCD4). This protein binds and inhibits the helicase activity of eIF4A (Zakowicz et al., 2005) . In a screen for novel targets of the E3 ubiquitin ligase bTRCP, Pagano and colleagues (Dorrello et al., 2006) identified PDCD4. Phosphorylation of PDCD4 by S6K increases binding to bTRCP and its subsequent degradation. This mechanism was shown to be important in regulating the translation of mRNAs containing highly structured 5 0 UTRs There is also evidence that mTORC1 might regulate protein synthesis via transcriptional modulation of RNA polymerases. In both yeast and human, rapamycin decreases ribosome biogenesis by inhibiting the transcription of rRNA genes by RNA polymerases I (Pol I), ribosomal proteins genes by Pol II, and tRNA and 5S rRNA synthesis by Pol III (for review see Mayer and Grummt, 2006) . The downstream substrates of mTORC1 that mediate these effects are currently unknown.
Inherited cancer predisposition syndromes implicating mTORC1
Further evidence for the importance of mTORC1-mediated translational regulation in human tumors has come from inherited genetic disorders that lead to an increased risk of cancer. This includes patients with Cowdens syndrome (inherited mutations in one copy of PTEN; Eng, 2003) , tuberous sclerosis (inherited mutations in one copy of TSC1 or TSC2; Kwiatkowski, 2003) , and Peutz-Jeghers disease (inherited mutations in one copy of LKB1; Alessi et al., 2006) . LKB1 is a serine/ threonine protein kinase essential for the activation of AMP kinase that occurs under conditions of increased energy stress. As mentioned previously, AMP kinase phosphorylates and activates TSC2. Therefore, loss of LKB1 activity causes elevated mTORC1 activity under conditions of energy stress. It is still unknown whether increased protein synthesis is the biological pathway downstream of mTORC1 relevant for tumor initiation in these syndromes, or which target mRNAs are important for this. Studies employing polysome purification and microarray analysis (also called translational profiling) under conditions of differing mTORC1 activity should help to understand this issue. Some experiments have recently begun to address this question.
mRNAs that are translationally regulated in tumor cells by mTORC1 and other pathways Microarray analysis of polysomal RNA isolated from rapamycin-treated Jurkat T cells using 6300 element Affymetrix arrays showed that 136 transcripts were depleted from polysomes under these conditions (Grolleau et al., 2002) . This group of mRNAs was highly enriched for ribosomal proteins, translation initiation factors and translation elongation factors, demonstrating empirically the importance of translational control downstream of mTORC1.
A separate study analyzed the effects of U0126 (a MEK inhibitor) and LY294002/rapamycin (a PI3-kinase inhibitor combined with an mTORC1 inhibitor) on total and polysomal associated RNAs in mouse glial progenitor cells expressing activated Ras and PKB/Akt (Rajasekhar et al., 2003) . In these experiments, expression of activated PKB/Akt or Ras had only a small effect on the activity of mTORC1, and a subsequent small effect on the polysomal localization of mRNAs. Expression of both caused a strong increase in mTORC1 signaling, and a subsequent redistribution of mRNAs between polysomes and subpolysomes. Inhibition of PI3-kinase/mTORC1 activity using LY294002 and rapamycin caused more rapid and extensive effects on polysomal RNA distribution compared to total RNA levels, suggesting that translation might be more important than transcription in mediating the shortterm effects of these inhibitors. Although many of the mRNAs identified as being differentially translated in response to Ras and PKB/Akt signaling have previously been implicated in oncogenesis, there was no obvious enrichment for either biologically related proteins, or for mRNAs with conserved motifs in 5 0 or 3 0 UTRs. We recently reported an analysis of polysomal RNA distributions in mouse embryonic stem cells lacking phosphoinositide dependent kinase-1 (Tominaga et al., 2005) . These cells display essentially no PKB/Akt or S6K activity yet mTORC1 activity (as assessed by 4E-BP1 phosphorylation) is unaffected (also shown in Wang et al., 2001) . Although global translation was decreased slightly, the polysomal recruitment of wellcharacterized 5 0 TOP containing mRNAs was not affected, confirming recent reports suggesting that S6K does not regulate the polysomal recruitment of TOP containing mRNAs (Pende et al., 2004; Ruvinsky et al., 2005) . In comparison, in a study using TSC1 and TSC2 null mouse embryo fibroblasts, in which mTORC1 activity is constitutively elevated, 5 0 TOP containing mRNAs are highly enriched in the group of mRNAs whose association with polysomes is regulated by serum in a TSC-dependent manner (Bilanges et al., 2006) . This confirms the notion that 5 0 TOP containing mRNAs are regulated in an mTORC1-dependent, but S6K-independent manner. Whether this is through the phosphorylation of 4E-BP1, or another substrate of mTORC1 such as STAT3 (Yokogami et al., 2000) is not known.
Translational profiling of NIH3T3 cells overexpressing eIF4E isolated a group of 255 genes that appear to be associated with the ability of eIF4E overexpression to rescue from serum starvation-induced apoptosis (Larsson et al., 2006;  Figure 1 ). Remarkably, suppression of a single gene, osteopontin, significantly reduced protection from apoptosis in these studies. In a similar study, transient overexpression of eIF4E in NIH3T3 cells resulted in the identification of 294 mRNAs that shifted from monosomes to polysomes (Mamane et al., 2007) . These include many RP genes, as well as the antiapoptotic genes survivin, Bl-1 and dad1.
A recent comparison of a colon cancer cell line (SW480) and its metastatic variant (SW620) analyzing total and polysomal RNA changes also came to the conclusion that translational alterations were more extensive that transcriptional alterations in mediating metastatic changes in this system (Provenzani et al., 2006) . The mRNAs showing changes in polysome distribution in this analysis possessed longer 5
0 UTRs compared to those that were regulated transcriptionally. Many genes involved in cell proliferation, RNA transport and metabolism, and the process of translation itself was enriched in this analysis.
Additional oncogenes and tumor suppressor genes and translational control
The t(9;22)(q34;q11) fusion, common in chronic myelogenous leukemia, creates the breakpoint cluster region/ abelson kinase (BCR/ABL) fusion protein. The role of BCR/ABL in translation regulation derives from studies showing that BCR/ABL tyrosine kinase activity affects the translation efficiency of several mRNAs encoding proteins involved in the regulation of cell survival, proliferation and differentiation. These mRNAs (MDM2, C/EBPa) contain in their 5 0 UTRs a consensus motif specific to certain RNA binding proteins (such as La and hnRNP E2) whose expression levels were enhanced by BCR/ABL activity. It was suggested that the RNA-binding protein La might play an important role in enhancing survival of cancer cells overexpressing BCR/ABL and might contribute to progression of CML. Another RNA-binding protein, hnRNP E2, regulated by BCR/ABL may be involved in the differentiation of CML myeloid progenitors through the translational repression of CCAAT/enhancer binding protein-a (C/EBPa), a regulator of granulocytic differentiation (Perrotti and Calabretta, 2004) .
The protein product of the breast cancer susceptibility gene BRCA1 was recently shown to interact with Poly(A) binding protein (PABP) (Dizin et al., 2006) . with PABP stabilizes the formation of the 'closed loop' structure of mRNAs important for the translation initiation process and facilitates the recycling of ribosomes after the termination of mRNA translation. Consistent with this, RNAi and overexpression studies confirmed a role for BRCA1 in increasing general protein synthesis.
Although less is known about how other commonly mutated oncogenes and tumor suppressors directly impact on translational regulation, it should be noted that myc increases the transcription of many ribosomal proteins, initiation factors, and rRNA ( Schmidt, 2004) , and p53 inhibits rRNA transcription (Zhai and Comai, 2000) . In addition, the levels of p53 itself are regulated by ribosomal proteins RPL5, RPL26 and RPL11 (Marechal et al., 1994; Takagi et al., 2005; Dai et al., 2006) .
Taken together, the data from all the above studies suggest that changes in mRNA translation play a major role in the ability of many oncogenes and tumor suppressor genes to transform cells. These observations also suggest that deregulated translation may represent opportunities for therapeutic intervention (see later).
Additional genetic alterations implicating mRNA translation in cancer
Although the importance of increased mRNA translation as a downstream pathway mediated by established oncogenes is becoming clear, dysregulation of individual components of the translational machinery in cancer has also been reported. In 2003, Ruggero and Pandolfi (2003) addressed in their review the exciting question: 'Does the ribosome translate cancer?' This is currently being answered by increasing evidence reporting the involvement of ribosome biogenesis dysfunction in cancer.
Genes involved in ribosomal biogenesis mutated in cancer susceptibility syndromes The most convincing evidence for a direct role of impaired ribosome biogenesis in the oncogenic process has been derived from investigations into cancer susceptibility syndromes. These studies have identified mutations and rearrangements in genes encoding proteins involved in ribosome biogenesis (DKC1 in Dyskeratosis congenita (DC), RPS19 in DiamondBlackfan anemia (DBA), RMRP in cartilage-hair hypoplasia (CHH)).
Dyskeratosis congenita. A cancer susceptibility syndrome directly associated with defects in ribosome biogenesis is DC. DC is a rare inherited disorder, characterized by premature ageing, bone marrow failure, and malignancy. 8-10% of DC patients develop tumors, consisting of haematological malignancies and tumors of various histological origins. DC exists in various patterns of inheritance: an X-linked recessive form and an autosomal-recessive form (Handley et al., 2006) . The X-linked form has been attributed to mutations of DKC1, a gene encoding a pseudouridine synthase (also known as dyskerin) involved in rRNA maturation, through post-transcriptional modification of rRNA (Figure 2a ). In addition, DKC1 is also associated with the RNA component of the telomerase complex (hTERC) and enhances its stability. The AD-DC form is caused by mutations in hTERC itself. However, the gene(s) responsible for the autosomal-recessive form is/ are still unknown. A recent study (Vulliamy et al., 2006) reported that more than 60% of the DC families tested do not harbor mutations in one of the genes cited above raising an exciting challenge to discover new DC genes. DC could therefore be caused by defects in ribosome biogenesis and/or defects in telomerase activity and/or some other biological process entirely. Support for the importance of ribosome biogenesis has arisen from a mouse model of DC. As loss of DKC1 is embryonic lethal, hypomorphic mice expressing reduced levels of DKC1 (70% lower than normal levels) have been generated, which are viable. Impairment of DKC1 function in these mice results in reduction of rRNA pseudouridylation. Fifty percent of these mice display an increased incidence of tumor formation, confirming the tumor suppressor function of DKC1. These mice show similarities of the human X-DC phenotype early in development and before the onset of the telomere shortening . Mice lacking mTERC develop short telomeres and also display, at later generations, features similar to the DC phenotype such as premature aging and chromosomal instability (Blasco et al., 1997) . Therefore, which of the two functions of dyskerin is more important for X-DC pathogenesis remains unclear. A recent study suggested that rRNA pseudouridine modifications and processing defects are not a universal feature of X-linked DC (Wong and Collins, 2006) . It is possible that the involvement of ribosome synthesis dysfunction or telomerase deregulation in the DC phenotype can contribute independently to create the specific features or severity of the human disorder. This hypothesis is supported by the fact that DKC1 is mutated in a more severe form of the disorder, the X-linked recessive form (or X-DC), whereas mutations in hTERC are found in the milder pattern of the disease, the autosomal-dominant form (or AD-DC). Thus, this may suggest that defects in ribosome function may contribute to a more severe phenotype. Mutational analysis of DKC1 from DC patients have identified specific mutations causing defects in only one of its two functions (Mochizuki et al., 2004) . A mouse model expressing these mutants of DKC1 would therefore be informative in resolving this issue.
The mechanism by which de-regulated ribosome function leads to cancer has been recently unraveled Translational deregulation in human tumors B Bilanges and D Stokoe using hypomorphic Dkc1 mutant mice and cells from X-DC patients (Yoon et al., 2006) . Yoon et al. (2006) showed that impaired pseudouridylation of rRNA results in impaired translation of specific mRNAs involved in cellular transformation rather than reduction of global protein synthesis. Such mRNAs (encoding the tumor suppressor p27 and anti-apoptotic proteins Bcl-XL and XIAP) contain an internal ribosomal entry site (IRES) in their 5 0 UTR sequences, known to bind the ribosome during translation initiation and to promote translation independently of a cap structure. Determining how DKC1 affects IRES-dependent translation should shed further insight into this disease.
Diamond-Blackfan anemia. This congenital syndrome is characterized by anemia, specific defects in erythropoiesis and increased risk of developing leukemia. Approximately 25% of both sporadic and inherited DBA cases are associated with mutations of the ribosomal protein 19 gene (RPS19) (Draptchinskaia et al., 1999) and haploinsufficiency is likely the pathological cause of DBA. RPS19 is required for maturation of 18S rRNA and thus plays an essential role in biogenesis of the 40S small ribosomal subunit in human cells (Choesmel et al., 2006; Flygare et al., 2006) . Recent studies strongly suggest that RPS19 mutation (or RPS19 haploinsuffiency) in DBA patients leads to impairment of ribosome biogenesis probably due to dysregulated stoichiometry of ribosomal components (Gazda et al., 2006;  Figure 2 ). Cells from RPS19-mutated patients show a global reduction of RP gene expression as well as downregulation of genes involved in translation (Gazda et al., 2006) . Whether or not RPS19 mutation is the underlying cause of DBA is still questionable. Global translational rates are reduced in DBA cells irrespective of RPS19 mutations indicating that inefficient translation may be the cause of DBA (Cmejlova et al., 2006; Koga et al., 2006) , but it also suggests that DBA patients with or without of RPS19 mutations cannot be distinguished by the level of translation. Mouse models have also not been informative in answering this question -homozygous rps19 À/À mice are embryonic lethal whereas heterozygous rps19 mice are viable with normal erythropoiesis and no apparent abnormalities (Matsson et al., 2006) . This may be due to a compensatory mechanism since the rps19 expression levels in the rsp19 þ /À mice are similar or even greater than normal control littermates.
Cartilage-hair hypoplasia. Another cancer susceptibility syndrome potentially involving a defect in ribosome biogenesis has been identified. CHH is a disease characterized by cartilage/skeletal defects, short stature, sparse hair, hypoplastic anemia, immune deficiency and predisposition to cancer (lymphoma). CHH is caused by a recessive mutation in the RMRP gene (Ridanpaa et al., 2001 ) encoding a RNA component of the RNase mitochondrial RNA processing (RMRP) complex, which plays a role in 5.8S rRNA processing (hence 60S ribosomal assembly; Figure 2 ). Little is known about the pathogenesis of CHH or the mechanism by which RMRP dysfunction leads to cancer predisposition. In yeast and human it has been shown that RMRP orthologs are involved in ribosome biogenesis, in mitochondrial DNA replication and in the degradation of cell-cycle regulated mRNAs (Gill et al., 2004; Thiel et al., 2005) . In vitro studies reported that alteration in RMRP function results in impairment in rRNA cleavage and cyclin B2 mRNA degradation through cleavage of its 5 0 UTR. Whether increased levels of cyclin B2 or other specific mRNAs are responsible of the CHH phenotype needs to be addressed in future experiments.
'Ribosome biogenesis defects and cancer' or 'Ribosomopathy' Approximately 80 ribosomal proteins (RPs) exist in mammals, and their coordinate assembly with the ribosomal RNAs (rRNAs) forms the large (60S) and small subunits (40S) of the ribosome. As the ribosome is essential for growth and development, aberrations in ribosome biogenesis result in severe phenotypes. Such aberrations have been observed in cancer and, paradoxically, result in either increased or reduced ribosome biogenesis.
Increased ribosome biogenesis is generally associated with increased cell growth and proliferation. In an empirical analysis of gene expression in colon and pancreatic cancer, many ribosomal proteins and initiation factors were overexpressed (Zhang et al., 1997) , and consequently are often used as prognostic markers for cancer. Many RP genes have been found overexpressed in colorectal cancer cells (Kitahara et al., 2001 ) and ovarian tumors (Welsh et al., 2001 ; Figure 2 ). However, it is not clearly established whether this aberrant expression represents a cause or a consequence of tumor formation. As cell-cycle control, mRNA translation and ribosome synthesis are closely connected, one could argue that overexpression of ribosomal proteins observed in tumors is a direct consequence of dysregulation of cell cycle progression and/or cell proliferation (Dez and Tollervey, 2004) . Strong evidence that ribosomal proteins are important for growth and proliferation come from previous studies in Drosophila. Heterozygous loss-of-function mutations in many RP genes display the Minute phenotype characterized by generally retarded development, infertility, and recessive lethality (Kongsuwan et al., 1985) . It is still not clear whether overexpression of RP genes seen in tumors results in upregulation of global protein synthesis, or whether the translation of individual mRNAs is more strongly affected. Translational profiling of primary tumor samples may help to resolve this issue.
Although increases in ribosome biogenesis have been correlated with malignant transformation (see above) there is also evidence that reduced ribosome biogenesis or loss of function of RP genes could also lead to disease and cancer. In zebrafish, for instance, many RPs act as haploinsufficient tumor suppressors as heterozygous mutations of 11 RPs predispose zebrafish to cancer (Amsterdam et al., 2004) . In support of RPs acting to prevent tumor growth, it was previously shown that overexpression of RP genes may be correlated with more differentiated and less aggressive ovarian tumors (Welsh et al., 2001) .
RPs may also possess extra-ribosomal activity apart from their role in protein synthesis. Growing evidences from studies carried in Drosophila and mammals suggest that this is the case for RPS3, RPS6 and RPS2 (Cramton and Laski, 1994) , RPL5 (Marechal et al., 1994) and RPL22 (Toczyski et al., 1994) . It has been reported that such extra-ribosomal functions might be important for tumorigenesis, including cellular stress responses, apoptosis and proliferation (reviewed in Liu and Ellis, 2006) .
In conclusion, there is evidence that both increases and/or decreases in both global and specific mRNA translation could lead to deregulated cell growth and proliferation and ultimately contribute to tumorigenesis. A simple explanation for these findings would be that under certain conditions increased ribosome biogenesis might enhance translation of mRNAs encoding oncogenes, whereas a decrease might shut off the translation of those encoding tumor suppressor genes. Future experiments should shed light on this speculative supposition.
Alterations of the eIF4F complex components
There is substantial evidence that some translation initiation/elongation factors can be directly involved in oncogenesis. The most compelling evidence for a direct role of aberrant control of translation in the oncogenic process has been derived from studies on translation initiation components and in particular on the eIF4F complex. eIF4F consists of the Cap-binding protein eIF4E, the scaffold protein eIF4G, the RNA helicase eIF4A and the helicase accessory factor eIF4B (reviewed in Morley, 2001) . Given that the rate of protein synthesis is mainly determined by the efficiency of translation initiation, it is not surprising that alterations of translation initiation factors may influence the translational rate of some proteins important for cell growth and oncogenesis. Indeed, many components of the eIF4F complex promote malignant transformation in vitro and are often overexpressed in various human tumors.
eIF4E. This was the first component of the translation initiation machinery known to cause deregulated cell growth and malignant transformation (Lazaris-Karatzas et al., 1990). eIF4E is overexpressed in a broad spectrum of human tumors, such as bladder, head and neck, liver, colon, bronchioalveolar and breast cancer (for a complete review, see Ruggero and Pandolfi, 2003; De Benedetti and Graff, 2004; Mamane et al., 2006 ; Figure 3 ), conferring to eIF4E the status of a valuable prognostic marker (Chen et al., 2004; Byrnes et al., 2006; Zhou et al., 2006) . This overexpression is thought to be caused by gene amplification, at least in head and neck cancer and breast cancer (Sorrells et al., 1999; Haydon et al., 2000) . Moreover, enhanced eIF4E function is often associated with recurrence of head and neck cancers as well as invasive and metastatic potential in certain human tumors (Graff and Zimmer, 2003) . The hypothesis that deregulated cap-dependent translation confers cancer susceptibility is strongly supported by in vivo studies using mouse models. Overexpression of eIF4E in transgenic mice results in tumor development 
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B Bilanges and D Stokoe from different histological origins (lung adenocarcinomas, angiosarcomas, lymphomas and hepatocellular adenomas; Ruggero et al., 2004) . In another mouse model, overexpression of eIF4E in an Em-Myc model of B-cell lymphoma accelerates lymphomagenesis (Wendel et al., 2004) . These studies thus indicate that eIF4E acts as an oncogene, however, the mechanism by which eIF4E functions to promote tumorigenesis is still unclear. It has been suggested that eIF4E transduces anti-apoptotic signals from the PKB/Akt pathway and abolishes c-myc-induced apoptosis in lymphomagenesis (Ruggero et al., 2004; Wendel et al., 2004) , perhaps by inhibiting the release of cytochrome c from the mitochondrial membranes (Li et al., 2003) . Constitutive sequestration of eIF4E by a non-phosphorylable mutant of 4E-BP1 induced apoptosis and suppressed tumorigenicity in breast carcinoma cells (Avdulov et al., 2004) , and partially reversed the transformed phenotype induced by c-myc (Lynch et al., 2004) . Importantly, overexpression of eIF4E does not increase global translation rates, but rather selectively stimulates translation of a subset of poorly translated mRNAs such as c-Myc, ODC, VEGF or cyclin D1. Although an attractive model of tumor progression and metastasis mediated by the preferential translation of these and other targets has been proposed (Graff and Zimmer, 2003) , the identity of the exact relevant targets has not been fully established (see e.g., Larsson et al., 2006; Mamane et al., 2007) .
eIF4G. Interestingly, Avdulov et al. (2004) showed that maintaining cap-dependent translation is critical for suppressing apoptosis and maintaining the tumorigenic phenotype of human breast cancer cells. In this study, the authors reported sustained eIF4F function in breast cancer cell lines, when compared to normal human mammary epithelial cells (HMECS), owing to overexpression of another component of the eIF4F complex, eIF4GI, and hyperphosphorylation of 4E-BP1 (likely owing to constitutive activity of mTORC1). Indeed, eIF4GI is overexpressed as a result of gene amplification in squamous lung carcinoma (Bauer et al., 2001 ; Figure 3 ), where eIF4E is not overexpressed. A causal role for eIF4GI in cancer is suggested by experiments in which overexpression caused malignant transformation in NIH 3T3 and tumor formation in nude mice (Fukuchi-Shimogori et al., 1997) .
eIF4A. Other components of the eIF4F complex have been also found altered in tumors, but their importance in tumorigenesis has not been demonstrated yet. For instance, the helicase eIF4A is overexpressed in human melanoma cell lines and primary hepatocellular carcinomas (Eberle et al., 1997; Shuda et al., 2000 ; Figure 3 ). Interestingly, eIF4A helicase activity is inhibited by the tumor suppressor PDCD4, preventing its association with the eIF4F complex (Yang et al., 2003) . Loss of PDCD4 expression in human tumor cell lines and primary carcinomas is correlated with tumor progression indicating that PDCD4 has a tumor suppressor function (Chen et al., 2003; Jansen et al., 2004) . Very recently, a study showed that PDCD4 suppresses tumorigenesis in vivo and acts as a translational repressor to control autoimmune inflammation (Hilliard et al., 2006; Figure 3) . Although global translational rates are increased in PDCD4 À/À cells, a small screen assay identified only three proteins (IL-10, IFN-g and IL-4) as being translationally regulated. It is not clear if these growth factors/cytokines are exclusively responsible for the lymphomagenesis and inflammation resistance observed in these mice. Additional experiments are required to determine whether eIF4A and eIF4F activity is enhanced in these cells and whether these cytokines are translationally regulated by eIF4F activity. If this is the case, it will support the hypothesis that unbalanced expression of translation initiation factors would affect the translation of specific mRNAs encoding proteins important for oncogenesis and cell growth. The presence of a highly structured GC-rich motif was shown to be present in the 5 0 UTRs of these mRNAs, suggesting that cells lacking PDCD4 increase eIF4A helicase activity to unwind complex structured 5 0 UTRs of specific mRNAs to facilitate their translation. Thus, identifying the mRNAs translationally regulated by PDCD4 would be critical to unravel the mechanism by which PDCD4, and hence eIF4A inhibition, suppresses tumorigenesis and controls inflammation.
4E-BP1.
The hypothesis that overexpression of eIF4E and increased cap-dependent translation enhances tumorigenesis is questioned by studies reporting the overexpression and dephosphorylation of 4E-BP1 in gastrointestinal cancer and oesophageal cancer (Martin et al., 2000; Salehi and Mashayekhi, 2006;  Figure 3 ). In the same tumors eIF4E is also overexpressed, and the levels of the eIF4E/4E-BP1 complexes are elevated in the tumor samples compared to the normal samples, suggesting that cap-dependent translation is shut off. Similar to the case of increased and decreased expression of ribosomal proteins seen in different tumors (as discussed above), this might reflect the different spectrum of growth promoting vs growth inhibitory proteins being expressed in different cells and conditions.
Other translational components
Although other initiation factors have been found overexpressed, their direct role in tumorigenesis is poorly documented. Initiation factor eIF3 is complex because some of its 13 putative subunits are either overexpressed or downregulated in human tumors (for a complete review on eIF3 see Dong and Zhang, 2006 ; Figure 3 ). For instance, amplification of the subunits eIF3-p110 in testicular cancers and eIF3-p40 in breast and prostate cancers have been reported whereas promoter hypermethylation likely accounts for the reduced level of eIF3-p48 subunit in non-small cell lung cancers (Nupponen et al., 2000; Okamoto et al., 2003; Buttitta et al., 2005) . It therefore raises the question of how such alterations can cause tumorigenesis. It seems Translational deregulation in human tumors B Bilanges and D Stokoe that some subunits might act differently to others within this complex. As an example, the subunit eIF3-p160/ p170 may act as an oncogene in regulating translation of specific mRNAs (such as p27Kip1, RRM2) important for cell proliferation (Dong and Zhang, 2003; Dong et al., 2004) . In contrast, the subunit eIF3-p47 may act as a tumor suppressor, because its expression is downregulated in several tumors from different histological origins and it has an anti-proliferative activity in vitro, probably by negatively regulating translation (by reducing ribosome assembly due to rRNA degradation).
The RNA-binding protein Y-Box-binding protein 1, YB-1, is overexpressed in large variety of tumors (breast, ovary, lung, colorectal and thyroid; Figure 3 ). YB-1 is a multifunction protein regulating transcription and translation depending on its cellular localization. In the cytoplasm, YB-1 controls translation in a dosedependent manner: low concentrations promote translation, whereas high concentrations inhibit cap-dependent and independent translation (Bader et al., 2003) . It is unclear how YB-1 inhibits translation. It has been suggested that YB-1 binds the cap structure of the mRNA and by competition displaces eIF4F complex from the mRNA thus inhibiting translation initiation (Nekrasov et al., 2003) . Another model suggests that YB-1 instead inhibits translation at a later stage of translation initiation by preventing mRNA scanning (Bader and Vogt, 2005) . In addition, phosphorylation of YB-1 by PKB/Akt reduces its cap-binding capacity thereby increasing translation initiation driven by eIF4F complex activity (Evdokimova et al., 2006) . Overexpression of YB-1 reverses PKB/Akt-induced transformation by inhibiting protein synthesis, suggesting that YB-1 has an anti-oncogenic function (Bader and Vogt, 2005) . However, YB-1 also acts as a transcriptional regulator and it has been shown that overexpression in ovarian and lung tumors is essentially nuclear suggesting that its transcriptional role predominates in these cancers (Matsumoto and Bay, 2005) .
Abnormal expression of other translational components are also found in human cancer and a comprehensive list published by Rajasekhar and Holland (2004) displays the large spectrum of human tumors harboring alterations of factors implicated in mRNA translation. Some elongation factors such as eEF1A2 act as putative oncogenes in ovarian cancer probably by inhibiting apoptosis (Anand et al., 2002) . EEF1A2 is overexpressed as a result of increased copy number in ovarian cancer, breast cancer (Tomlinson et al., 2005) as well as in lung adenocarcinoma . Other components of the translational machinery are found overexpressed in human cancers such as eIF2B, eIF5A, elongation factor eEF1-g and dsRNA-dependent protein kinase PKR, but their direct role in tumorigenesis remains to be determined (Figure 3) .
Finally, S6K, a key effector of the PI3-K/mTOR pathway (see section above) and important for cell growth and translational regulation, has been found overexpressed as a result of gene amplification in anaplastic meningiomas (Cai et al., 2001 ) and breast cancer and has been subsequently associated with a poor prognosis (Couch et al., 1999; Barlund et al., 2000 ; Figure 3 ). Importantly, Barlund et al. (2000) showed that increased S6K levels were associated with increased activity suggesting a putative oncogenic role for S6K in tumorigenesis.
miRNAs and cancer Although many outstanding reviews have already been published on this topic (Calin and Croce, 2006; EsquelaKerscher and Slack, 2006) it is important to reiterate the likely importance of this new area in mRNA translation and cancer. microRNAs (miRNAs) are non-proteincoding, endogenous, small RNAs (20-25 nt in length). miRNA regulates gene expression by cleavage of the targeted mRNA via perfect complementarity or by translational repression via a nearly perfect complementarity at the 3 0 UTR of a targeted mRNA (Figure 3 ). Genome-wide expression analysis and bioinformatics approaches have estimated the number of human miRNAs as many as 800 (Bentwich, 2005) , although the identification of additional miRNAs in tissues not yet tested might considerably extend this number. The involvement of miRNA in cancer stems from studies reporting genetic alterations (amplification, deletion, mutation) of miRNA genes in several cancers including B-cell lymphoma, breast, lung, prostate and ovarian cancers (for a complete review see Esquela-Kerscher and Slack, 2006) . About 50% of miRNAs are located at fragile sites (regions known to be amplified or deleted). Changes in miRNAs expression levels have been also documented, suggesting that miRNA levels can be used as diagnostic or prognostic markers. As previously described for ribosomal proteins (see above), it is not clear whether these aberrant expression changes are the direct cause of tumorigenesis or a consequence of the malignant transformation. However, growing evidences indicate that some miRNAs can act as oncogenes or tumor suppressors (for review see Kent and Mendell, 2006) . The most compelling evidences for the oncogenic role of miRNA are derived from studies on B-cell lymphoma. A cluster containing several miRNA genes (mir-17 cluster) is amplified in B-cell lymphoma. Many transgenic mouse models overexpressing miRNAs (such as mir-155 or cluster mir-17) indicate that they are sufficient to induce or accelerate tumorigenesis in mice (He et al., 2005; Costinean et al., 2006) supporting the hypothesis that miRNAs act as oncogenes. Increased expression levels of the mir-17 cluster are also observed in breast, colon, prostate and lung cancer, particularly in the most aggressive form of lung cancer. However, there is also evidence that miRNAs can act as tumor suppressors. Surprisingly, loss of heterozygosity in the genomic region harboring the mir-17 cluster was detected in other types of cancers (including breast, bladder, hepatocellular carcinomas and pituitary adenomas) suggesting that mir-17 function depends on its cellular context. Other genomic regions containing miRNAs are deleted in various human cancers (B-cell chronic lymphocytic leukemia, multiple myeloma, prostate cancer for mir15a and mir16-1, lung, breast and ovary cancer for the let-7 family) (Calin et al., 2002 (Calin et al., , 2004 and decreased expression of others has been detected in tumors (colorectal, breast for mir-143 and mir-145; Michael et al., 2003; Iorio et al., 2005) . A more comprehensive list of putative miRNA oncogenes or tumor suppressors is published in Kent and Mendell (2006) .
The miRNA functions, either oncogenic or tumor suppressive, are mainly mediated through the regulation of their specific targets that are involved in cell proliferation and apoptosis. For instance, the antiproliferative activity of mir-15 and mir-16-1 is likely owing to the translational inhibition of BCL2 via their interactions with BCL2 3 0 UTR (Cimmino et al., 2005) . Similarly, the growth suppressive properties of let-7 may be owing to the negative regulation of the human oncogenes N-Ras and K-Ras in lung cancer (Johnson et al., 2005) . In contrast, the oncogenic activity of mir-17 cluster may be due to the translational repression of the tumor suppressor PTEN, whereas its anti-proliferative activity is attributed to the repression of E2F1 expression thus conferring its tumor suppressor function (Calin and Croce, 2006) .
Importantly, bioinformatic analysis have predicted that miRNAs regulate approximately 30% of human targets (Cummins and Velculescu, 2006) , suggesting their large spectrum of function in humans. Therefore, depending on the cellular context, the abundance of these targets and the existence of other genomic alterations, it is likely that alteration in miRNA expression levels lead to aberrant expression of several targets contributing to cancer.
Therapeutic opportunities

Rapamycin and analogs
As well as mediating oncogenic transformation and metastasis, translational alterations in human tumors may present opportunities for therapeutic intervention. The most advanced application of this concept is through the uses of rapamycin and its newer synthetic derivatives. As rapamycin potently inhibits the proliferation of T cells (Dumont et al., 1990) , it was approved as an immunosuppressive drug in 1999. Although rapamycin was shown to possess anti-tumor properties over 20 years ago (Eng et al., 1984) , it was never taken forward into cancer patients. However, as more information on the role of mTORC1 in human tumors has emerged, the application of rapamycin for this indication is being reevaluated. Modified versions of rapamycin, such as CCI-779 (rapamycin-42,2,2-bis(hydroxymethyl)-propionic acid), RAD-001 (40-O-(2-hydroxymethyl)-rapamycin) and AP23573 (a phosphorylated form of rapamycin) are currently in various stages of clinical trials. The above represent only subtle chemical modifications to rapamycin purified from Streptomyces hygroscopicus, due to the lack of available reactive chemical groups. More dramatically altered derivatives of rapamycin can be produced by creating different strains of S. hygroscopicus mutated in various genes involved in the biosynthetic process (e.g., Gregory et al., 2005) , which may provide additional benefits in potency and/or pharmacokinetics/ biodistribution.
In general, rapamycin analogues do not demonstrate potent antitumor activity in Phase 2 trials currently reported (reviewed in Easton and Houghton, 2006) . Nevertheless, some tumor types seem to be more responsive to the agents, and it is highly likely that molecular features of individual tumors will determine responses. In a Phase 2 trial of renal cell carcinoma (RCC) patients, 7% (8/111 patients) demonstrated a complete or partial response. Preclinical experiments from Sawyers and colleagues suggest a potential link between the genetics of RCC and response to rapamycin. The von-Hippel-Lindau (VHL) gene is mutated in patients with both inherited and sporadic kidney cancers. VHL is an E3 ubiquitin ligase that causes the degradation of the hypoxia inducible factor 1a (HIF1a) protein when oxygen levels are abundant. Therefore when VHL is mutated HIF1a levels are increased owing to lack of degradation. Thomas et al. recently showed that kidney tumors lacking VHL show an increased sensitivity to rapamycin, which is probably owing in part to the requirement for mTORC1 activity to translate HIF1a mRNA (Thomas et al., 2006) . HIF1 is a transcription factor that induces the expression of multiple glycolytic enzymes, perhaps helping to explain the increases in glycolysis seen both in human tumors (Plas and Thompson, 2005) , and in mouse models of neoplasia (Majumder et al., 2004) . However, a simple relationship between VHL and rapamycin sensitivity is complicated by the fact that mTORC1 activity has shown to be decreased under conditions of hypoxia (Brugarolas et al., 2004) , and that VHL is mutated in a greater number of RCCs than those responding to rapamycin analogs.
Additional molecular features determining increased sensitivity to rapamycin or its analogs include mutated or decreased levels of PTEN (Neshat et al., 2001; DeGraffenried et al., 2004) , increased phospho-S6K levels (Yu et al., 2001; Noh et al., 2004; Galanis et al., 2005) and either increased (Noh et al., 2004) or decreased (Law et al., 2006) cyclin D1 levels. Interestingly, rapamycin was shown to cause differential polysomal mobilization of cyclin D1 and myc mRNAs depending on rapamycin sensitivity to growth arrest (Gera et al., 2004) . Cells expressing high levels of PKB/ Akt phosphorylation were growth inhibited by rapamycin, which caused decreases in the polysome association of cyclin D1 and c-myc mRNA. In contrast, cells expressing low levels of phosphorylated PKB/Akt did not undergo a G1 arrest in response to rapamycin, which caused increased polysome association of cyclin D1 and c-myc. Remarkably, expression of chimeric cyclin D1 and c-myc RNAs with a p27 kip1 IRES in their 5 0 UTR was sufficient to prevent the G1 arrest induced by rapamycin in cells expressing high levels of phosphorylated PKB/Akt (Gera et al., 2004) . This demonstrates that rapamycin displays growth inhibitory properties due at least in part to the selective In addition to modest anti-tumor effects of rapamycin analogues when used as a single agent, these drugs are attractive combinatorial agents. This has been demonstrated experimentally for conventional DNA damaging chemotherapeutic agents such as cisplatin (Beuvink et al., 2005) and radiation (Eshleman et al., 2002; Shinohara et al., 2005) . Rapamycin has also been proposed as a combination therapy with emerging molecularly targeted therapies such as EGFR inhibitors (Rao et al., 2005; Wang et al., 2006) . A novel mechanism for combination of rapamycin and TRAIL was recently proposed. TRAIL (tumor necrosis factor-related apoptosis-Inducing Ligand) is a pro-apoptotic ligand of the tumor necrosis factor superfamily. TRAIL is an attractive anticancer agent owing to its selective ability to cause apoptosis of tumor cells relative to non-tumor cells. However, not all tumor cells are equally susceptible to TRAIL-induced death. Panner et al. (2005) showed that increased levels of the short isoform of the anti-apoptotic protein FLICE-inhibitory protein (FLIPs) predicted resistance to TRAIL induced apoptosis. The levels of FLIPs were high in tumor cells with increased mTORC1 activity, and this was shown to be owing to its increased polysome accumulation translation. Addition of rapamycin or reduction of S6K1 levels using siRNA reduced FLIPs translation and restored sensitivity to TRAIL (Panner et al., 2005) . Although TRAIL is not yet in human clinical trials, these experiments may be useful in selecting patients that might preferentially respond to this agent, as well as providing appropriate drug combination strategies.
Selective translational expression of killer genes in tumor cells
As previously mentioned, several experiments have shown that activation of the eIF4F complex may be particularly important for the translation of mRNAs with long and complex 5 0 UTRs. The importance of this process in tumorigenesis is demonstrated by the amplification and overexpression of eIF4F components in human tumors, such as eIF4E and eIF4G (Haydon et al., 2000; Avdulov et al., 2004) . This finding has been utilized to express suicide genes such as herpes simplex virus type-1 thymidine kinase gene (HSV-TK) downstream of a long and structured 5 0 UTR. The logic behind this approach is that the low levels of eIF4E activity found in normal cells would only support minimal translation of such a chimeric mRNA, whereas the elevated eIF4E expression and/or activity found in tumor cells would allow translation of the HSV-TK gene. Systemic administration of the prodrug gancyclovir would then be expected to be benign in normal tissues, but converted into its toxic phosphorylated product only in tumor cells. This concept was demonstrated using the 5 0 UTR of rat FGF2 (619 bases, stability of À55 kcal/mol) upstream of the gancyclovir open reading frame (DeFatta et al., 2002) . These experiments demonstrated that tumor cells expressing the chimeric HSV-TK RNA could be killed at up to 500-fold lower concentrations of gancyclovir than normal cells, in a manner that was dependent on eIF4E expression (DeFatta et al., 2002) . This concept was extended by using either a lentivirus or adenovirus (Mathis et al., 2006) to deliver such constructs, as well as adding a prostate specific promoter to drive expression specifically in prostate epithelial cells . In each case, increased expression of the HSV-TK protein was seen in tumor cells, with an associated increased sensitivity to gancyclovir. Targeted delivery of suicide genes followed by systemic pro-drug delivery is still a relatively new approach to cancer therapy. However, intratumoral expression of HSV-TK and subsequent parenteral delivery of gancyclovir has been shown to be relatively safe and effective in patients with localized prostate cancer (Ayala et al., 2006) .
Oncolytic viral replication owing to tumor-associated translational defects At least two additional virus-based approaches for selective killing of tumor cells based on translational differences between normal and tumor cells have been proposed. Reovirus is a double-stranded RNA virus, which is asymptomatically present in most humans. However, several years ago it was noted that this virus replicates more efficiently in transformed cells relative to normal cells (Duncan et al., 1978) . More recently, it was found that growth factor-dependent signaling such as triggered by EGFR or Ras underlies this selectivity. Infection and viral gene transcription were both equal in untransformed and Ras-transformed cells, whereas viral protein expression was restricted to the Ras-transformed cells only, suggesting a block in translation in the untransformed cells (Strong et al., 1998) . Subsequent studies showed that reovirus infection of non-transformed cells results in the activation of the doublestranded RNA-activated protein kinase PKR, and the resultant phosphorylation of its substrate eIF2a. Phosphorylation of this translation initiation factor prevents the assembly of the 43S small ribosomal subunit preinitiation complex, thereby blocking global translation (reviewed in Kaufman, 2000) , as well as translation of viral proteins. In contrast, reovirus infection of Rastransformed cells did not result in activation of PKR, allowing translation of viral proteins and productive infection. Tumor-specific reovirus replication has been extended to a panel of ovarian, colon , breast and brain tumors (Yang et al., 2004a) , as well as in metastatic models (Hirasawa et al., 2003) . Reovirus is currently in Phase 2 clinical trials following demonstration of safety in Phase 1 trials. Although reovirus infection represents a promising tumor-specific oncolytic virus, many questions still remain, such as the mechanism whereby Ras activity prevents the activation of PKR. Interestingly, this has been shown to be independent of MEK/ERK activity, but dependent on activation of Ral/p38 MAPK downstream of Ras (Norman et al., 2004) .
Another virus that appears to possess intrinsic tropism for replicating in tumor cells relative to normal cells is the single-stranded RNA virus vescicular stomatitis virus (VSV) (Balachandran and Barber, 2000) . Activation of PKR by double-stranded RNA produced during viral infection appears to be an important checkpoint restricting the replication of VSV in normal cells, similar to that seen upon reovirus infection. In support of this, fibroblasts lacking PKR supported approximately 10-fold greater VSV replication compared to PKR þ / þ fibroblasts. However, PKR status is clearly not the only factor in determining sensitivity to VSV infection and replication, as several permissive cells show PKR activation and eIF2a phosphorylation following infection (Balachandran and Barber, 2004) . Instead, these authors postulate that elevated levels of eIF2Be, the guanine nucleotide exchange factor for the eIF2a G protein, maintains intracellular protein synthesis in permissive VSV-infected cells (Balachandran and Barber, 2004) . Consistent with this finding, these authors demonstrate increased levels of eIF2Be in many primary human tumors relative to their matched normal tissues (Balachandran and Barber, 2004) . This suggests that increased translation initiation by maintaining high levels of eIF2a GTP levels, either through Ras inhibition of PKR or elevated levels of eIF2Be, is a common feature of human tumors. A causal role for this dysregulation in tumorigenesis is suggested by the observation that overexpression of a mutant of eIF2a that cannot be phosphorylated by PKR (or other kinases) results in transformation of immortalized cells (Donze et al., 1995) . This is consistent with the finding that cells expressing only the non-phosphorylable mutant of eIF2a are resistant to apoptosis induced by a variety of stimuli (Scheuner et al., 2006) . More recently, mutated versions of VSV have been engineered that display decreased replication in normal cells, but maintain replicative ability in most tumor cells (Stojdl et al., 2003) . These mutants result in an enhanced interferon response following infection of normal untransformed cells which curtails virus spread, and take advantage of the fact that tumor cells are generally defective in mounting an interferon-mediated response following virus infections, allowing efficient virus spread throughout the tumor (Stojdl et al., 2003) .
Conclusions
Studies performed over the last 40 years or so have progressed from 1. Observations that increased protein synthesis occurs in tumor cells (Weber and Lea, 1966) , to 2. Demonstration that increased mRNA translation represents a critical function downstream of commonly mutated oncogenes and tumor suppressor proteins, to 3. Finding that mutations in components of the translational apparatus are found in, and are critical for the development of, human cancers. This fundamental understanding of the role mRNA translation plays in the initiation and progression of human tumors has afforded an opportunity for therapeutic intervention. This is currently being realized in the use of rapamycin analogs to inhibit deregulated translation initiated by increased mTORC1 activity, and oncolytic viruses that require defective translational regulation present in tumor cells for their replication. Further insight into which mRNAs are preferentially translated in response to these deregulated pathways, and their specific roles in tumorigenesis, will undoubtedly lead to new therapeutic targets. These new mRNA targets may also be considered as biomarkers that will dictate the circumstances under which their inhibition will be most effective.
